KR102267927B1 - Tor 키나제 억제제를 사용한 전립선암의 치료 - Google Patents

Tor 키나제 억제제를 사용한 전립선암의 치료 Download PDF

Info

Publication number
KR102267927B1
KR102267927B1 KR1020207026267A KR20207026267A KR102267927B1 KR 102267927 B1 KR102267927 B1 KR 102267927B1 KR 1020207026267 A KR1020207026267 A KR 1020207026267A KR 20207026267 A KR20207026267 A KR 20207026267A KR 102267927 B1 KR102267927 B1 KR 102267927B1
Authority
KR
South Korea
Prior art keywords
substituted
unsubstituted
pyrazin
formula
tor kinase
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207026267A
Other languages
English (en)
Korean (ko)
Other versions
KR20200108923A (ko
Inventor
데보라 모텐슨
헤더 레이몬
라마 케이 날라
크리스틴 매 헤지
킴벌리 엘리자베스 펄츠
토시야 츠지
Original Assignee
시그날 파마소티칼 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 시그날 파마소티칼 엘엘씨 filed Critical 시그날 파마소티칼 엘엘씨
Publication of KR20200108923A publication Critical patent/KR20200108923A/ko
Application granted granted Critical
Publication of KR102267927B1 publication Critical patent/KR102267927B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/08Drugs for disorders of the urinary system of the prostate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Inorganic Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020207026267A 2012-10-18 2013-10-17 Tor 키나제 억제제를 사용한 전립선암의 치료 Active KR102267927B1 (ko)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201261715510P 2012-10-18 2012-10-18
US61/715,510 2012-10-18
PCT/US2013/065363 WO2014062878A2 (en) 2012-10-18 2013-10-17 Treatment of cancer with tor kinase inhibitors
KR1020157012636A KR102157914B1 (ko) 2012-10-18 2013-10-17 Tor 키나제 억제제를 사용한 전립선암의 치료

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020157012636A Division KR102157914B1 (ko) 2012-10-18 2013-10-17 Tor 키나제 억제제를 사용한 전립선암의 치료

Publications (2)

Publication Number Publication Date
KR20200108923A KR20200108923A (ko) 2020-09-21
KR102267927B1 true KR102267927B1 (ko) 2021-06-21

Family

ID=50023830

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020207026267A Active KR102267927B1 (ko) 2012-10-18 2013-10-17 Tor 키나제 억제제를 사용한 전립선암의 치료
KR1020157012636A Active KR102157914B1 (ko) 2012-10-18 2013-10-17 Tor 키나제 억제제를 사용한 전립선암의 치료

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020157012636A Active KR102157914B1 (ko) 2012-10-18 2013-10-17 Tor 키나제 억제제를 사용한 전립선암의 치료

Country Status (19)

Country Link
US (1) US20140113904A1 (enExample)
EP (1) EP2908814B1 (enExample)
JP (3) JP2015534981A (enExample)
KR (2) KR102267927B1 (enExample)
CN (2) CN110721186A (enExample)
AU (1) AU2013202768B2 (enExample)
BR (1) BR112015008834A2 (enExample)
CA (1) CA2888609C (enExample)
EA (1) EA029164B1 (enExample)
ES (1) ES2777936T3 (enExample)
IL (1) IL238326B (enExample)
MX (1) MX368407B (enExample)
MY (1) MY176599A (enExample)
NI (1) NI201500055A (enExample)
PH (2) PH12020550858A1 (enExample)
SG (2) SG11201502999YA (enExample)
UA (1) UA117000C2 (enExample)
WO (1) WO2014062878A2 (enExample)
ZA (1) ZA201503105B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013203714B2 (en) 2012-10-18 2015-12-03 Signal Pharmaceuticals, Llc Inhibition of phosphorylation of PRAS40, GSK3-beta or P70S6K1 as a marker for TOR kinase inhibitory activity
EP2945636B1 (en) 2013-01-16 2017-06-28 Signal Pharmaceuticals, LLC Substituted pyrrolopyrimidine compounds, compositions thereof, and methods of treatment therewith
US9737535B2 (en) 2014-04-16 2017-08-22 Signal Pharmaceuticals, Llc Methods for treating cancer using TOR kinase inhibitor combination therapy comprising administering substituted pyrazino[2,3-b]pyrazines
NZ629796A (en) 2014-07-14 2015-12-24 Signal Pharm Llc Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use
AU2015289929A1 (en) 2014-07-14 2017-03-02 Signal Pharmaceuticals, Llc Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof
JP6964343B2 (ja) * 2015-11-20 2021-11-10 フォーマ セラピューティクス,インコーポレイテッド ユビキチン特異的プロテアーゼ1阻害剤としてのプリノン
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
CN110403943B (zh) * 2019-08-19 2022-05-17 陕西科技大学 Cc-115在制备抗真菌药物中的应用及其药物组合物

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100216781A1 (en) * 2008-10-27 2010-08-26 Sophie Perrin-Ninkovic mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1159582C (zh) * 2001-12-08 2004-07-28 云南大学 一种人体全血或血清总前列腺特征性抗原值,总前列腺特征性抗原灰区值检测方法
GB0509748D0 (en) 2005-05-13 2005-06-22 Univ Glasgow Materials and methods relating to cell based therapies
US20070238745A1 (en) * 2006-04-07 2007-10-11 University Of South Florida PI3K-Akt Pathway Inhibitors
ES2383370T3 (es) 2006-10-19 2012-06-20 Signal Pharmaceuticals Llc Compuestos de heteroarilo, sus composiciones y uso de los mismos como inhibidores de proteína quinasa
EP2457913B1 (en) * 2006-10-19 2017-04-19 Signal Pharmaceuticals, LLC Heteroaryl compounds, compositions thereof, and methods of treatment therewith
EP2349984A1 (en) * 2008-10-17 2011-08-03 Merck & Co. Combination therapy
JP2013508456A (ja) * 2009-10-26 2013-03-07 シグナル ファーマシューティカルズ, エルエルシー ヘテロアリール化合物の合成方法および精製方法
US20120238562A1 (en) * 2011-03-09 2012-09-20 Cedars-Sinai Medical Center Treatment of cancer by targeting molecules that influence mst1/stk4 signaling

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100216781A1 (en) * 2008-10-27 2010-08-26 Sophie Perrin-Ninkovic mTOR KINASE INHIBITORS FOR ONCOLOGY INDICATIONS AND DISEASES ASSOCIATED WITH THE mTOR/PI3K/AKT PATHWAY

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
a systematic review, (2011)*

Also Published As

Publication number Publication date
CA2888609C (en) 2020-12-01
CA2888609A1 (en) 2014-04-24
MX368407B (es) 2019-10-02
US20140113904A1 (en) 2014-04-24
WO2014062878A2 (en) 2014-04-24
PH12015500867B1 (en) 2015-06-22
CN110721186A (zh) 2020-01-24
WO2014062878A3 (en) 2014-06-26
EP2908814B1 (en) 2019-12-25
EP2908814A2 (en) 2015-08-26
JP7162543B2 (ja) 2022-10-28
KR102157914B1 (ko) 2020-09-18
NI201500055A (es) 2015-09-10
EA201590744A1 (ru) 2015-11-30
WO2014062878A9 (en) 2014-12-18
JP2019081771A (ja) 2019-05-30
PH12015500867A1 (en) 2015-06-22
ES2777936T3 (es) 2020-08-06
KR20150070319A (ko) 2015-06-24
SG10201810575WA (en) 2019-01-30
JP2021050213A (ja) 2021-04-01
AU2013202768B2 (en) 2015-11-05
ZA201503105B (en) 2016-11-30
SG11201502999YA (en) 2015-05-28
EA029164B1 (ru) 2018-02-28
PH12020550858A1 (en) 2023-02-20
BR112015008834A2 (pt) 2017-07-04
IL238326B (en) 2018-03-29
JP2015534981A (ja) 2015-12-07
UA117000C2 (uk) 2018-06-11
IL238326A0 (en) 2015-06-30
KR20200108923A (ko) 2020-09-21
MX2015004874A (es) 2015-08-05
CN105050601A (zh) 2015-11-11
MY176599A (en) 2020-08-18
AU2013202768A1 (en) 2014-05-08

Similar Documents

Publication Publication Date Title
KR102057357B1 (ko) Tor 키나제 억제제를 사용한 암의 치료
KR102057358B1 (ko) Tor 키나제 억제제를 사용한 암의 치료
EP2909627B1 (en) Inhibition of phosphorylation of pras40, gsk3-beta or p70s6k1 as a marker for tor kinase inhibitory activity
KR102267927B1 (ko) Tor 키나제 억제제를 사용한 전립선암의 치료
KR20210071101A (ko) Tor 키나제 억제자를 사용하는 암의 치료
AU2015213397B2 (en) Treatment of cancer with TOR kinase inhibitors
HK40013177A (en) Treatment of prostate cancer with tor kinase inhibitors
HK1202247B (en) Treatment of cancer with tor kinase inhibitors
HK1213049B (en) Inhibition of phosphorylation of pras40, gsk3-beta or p70s6k1 as a marker for tor kinase inhibitory activity
HK1201755B (en) Treatment of cancer with tor kinase inhibitors
HK1201750B (en) Treatment of cancer with tor kinase inhibitors

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20200911

Application number text: 1020157012636

Filing date: 20150514

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20201028

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210428

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20210616

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20210616

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20240514

Start annual number: 4

End annual number: 4